Faculty Opinions recommendation of Ferric carboxymaltose for iron deficiency at discharge after acute heart failure: a multicentre, double-blind, randomised, controlled trial.

Iron Deficiency ◽

Acute Heart Failure ◽

Controlled Trial ◽

Ferric Carboxymaltose ◽

Double Blind ◽

Ferric carboxymaltose for iron deficiency at discharge after acute heart failure: a multicentre, double-blind, randomised, controlled trial

The Lancet ◽

10.1016/s0140-6736(20)32339-4 ◽

2020 ◽

Vol 396 (10266) ◽

pp. 1895-1904 ◽

Cited By ~ 9

Author(s):

Piotr Ponikowski ◽

Bridget-Anne Kirwan ◽

Stefan D Anker ◽

Theresa McDonagh ◽

Maria Dorobantu ◽

...

Keyword(s):

Heart Failure ◽

Iron Deficiency ◽

Acute Heart Failure ◽

Controlled Trial ◽

Ferric Carboxymaltose ◽

Double Blind ◽

Faculty Opinions recommendation of The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.717955094.793462652 ◽

2012 ◽

Author(s):

Chim Lang

Keyword(s):

Heart Failure ◽

Controlled Trial ◽

Preserved Ejection Fraction ◽

Phase 2 ◽

Angiotensin Receptor ◽

Double Blind ◽

Neprilysin Inhibitor ◽

Angiotensin Receptor Neprilysin Inhibitor ◽

The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial

The Lancet ◽

10.1016/s0140-6736(12)61227-6 ◽

2012 ◽

Vol 380 (9851) ◽

pp. 1387-1395 ◽

Cited By ~ 637

Author(s):

Scott D Solomon ◽

Michael Zile ◽

Burkert Pieske ◽

Adriaan Voors ◽

Amil Shah ◽

...

Keyword(s):

Heart Failure ◽

Controlled Trial ◽

Preserved Ejection Fraction ◽

Phase 2 ◽

Angiotensin Receptor ◽

Double Blind ◽

Neprilysin Inhibitor ◽

Angiotensin Receptor Neprilysin Inhibitor ◽

Rationale and design of the AFFIRM‐AHF trial: a randomised, double‐blind, placebo‐controlled trial comparing the effect of intravenous ferric carboxymaltose on hospitalisations and mortality in iron‐deficient patients admitted for acute heart failure

European Journal of Heart Failure ◽

10.1002/ejhf.1710 ◽

2019 ◽

Vol 21 (12) ◽

pp. 1651-1658 ◽

Cited By ~ 11

Author(s):

Piotr Ponikowski ◽

Bridget‐Anne Kirwan ◽

Stefan D. Anker ◽

Maria Dorobantu ◽

Jarosław Drozdz ◽

...

Keyword(s):

Heart Failure ◽

Acute Heart Failure ◽

Controlled Trial ◽

Ferric Carboxymaltose ◽

Double Blind ◽

Double Blind Placebo ◽

Iron Deficient

Comparison of ferric Carboxymaltose and iron sucrose complex for treatment of iron deficiency anemia in pregnancy- randomised controlled trial

BMC Pregnancy and Childbirth ◽

10.1186/s12884-019-2200-3 ◽

2019 ◽

Vol 19 (1) ◽

Cited By ~ 6

Author(s):

Ambily Jose ◽

Reeta Mahey ◽

Jai Bhagwan Sharma ◽

Neerja Bhatla ◽

Renu Saxena ◽

...

Keyword(s):

Iron Deficiency ◽

Iron Deficiency Anemia ◽

Controlled Trial ◽

Iron Sucrose ◽

Deficiency Anemia ◽

Ferric Carboxymaltose ◽

Anemia In Pregnancy ◽

Randomised Controlled ◽

In Pregnancy

Reflexology has no immediate haemodynamic effect in patients with chronic heart failure: A double blind randomised controlled trial

Complementary Therapies in Clinical Practice ◽

10.1016/j.ctcp.2013.03.004 ◽

2013 ◽

Vol 19 (3) ◽

pp. 133-138 ◽

Cited By ~ 10

Author(s):

Jenny Jones ◽

Patricia Thomson ◽

William Lauder ◽

Kate Howie ◽

Stephen J. Leslie

Keyword(s):

Heart Failure ◽

Chronic Heart Failure ◽

Controlled Trial ◽

Haemodynamic Effect ◽

Double Blind ◽

Faculty Opinions recommendation of The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.717955094.793467314 ◽

2012 ◽

Author(s):

Jerome Fleg

Keyword(s):

Heart Failure ◽

Controlled Trial ◽

Preserved Ejection Fraction ◽

Phase 2 ◽

Angiotensin Receptor ◽

Double Blind ◽

Neprilysin Inhibitor ◽

Angiotensin Receptor Neprilysin Inhibitor ◽

A MULTICENTRE DOUBLE-BLIND RANDOMISED CONTROLLED TRIAL TO ASSESS THE CLINICAL- AND COST-EFFECTIVENESS OF FACET-JOINT INJECTIONS IN PATIENTS WITH NON-SPECIFIC LOW BACK PAIN: A FEASIBILITY STUDY

10.26226/morressier.59ad4811d462b80290b53a8a ◽

2017 ◽

Author(s):

Ahmad Alia

Keyword(s):

Low Back Pain ◽

Back Pain ◽

Cost Effectiveness ◽

Facet Joint ◽

Controlled Trial ◽

Low Back ◽

Double Blind ◽

Randomised Controlled ◽

Joint Injections

Faculty Opinions recommendation of TCH346 as a neuroprotective drug in Parkinson's disease: a double-blind, randomised, controlled trial.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.1058963.510919 ◽

2007 ◽

Author(s):

Pascal Derkinderen

Keyword(s):

Parkinson’S Disease ◽

Parkinson's Disease ◽

Controlled Trial ◽

Double Blind ◽

Faculty Opinions recommendation of Efficacy of combined antiparasitic therapy with praziquantel and albendazole for neurocysticercosis: a double-blind, randomised controlled trial.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.718482844.793498728 ◽

2014 ◽

Author(s):

Carlos Seas ◽

Joel Lopez

Keyword(s):

Controlled Trial ◽

Double Blind ◽